Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study by unknown
RESEARCH Open Access
Flow cytometry remission by Ig light chains
ratio is a powerful marker of outcome in
multiple myeloma after tandem autologous
transplant: a real-life study
Iole Cordone1,4*, Francesco Marchesi2, Serena Masi1, Valentina Summa1, Francesco Pisani2, Roberta Merola1,
Giovanni Cigliana1, Giulia Orlandi1, Svitlana Gumenyuk2, Francesca Palombi2, Atelda Romano2, Antonio Spadea2,
Daniela Renzi2, Elena Papa2, Marco Canfora3, Laura Conti1, Maria Concetta Petti2 and Andrea Mengarelli2
Abstract
Background: The achievement of complete response (CR) significantly correlates with a better clinical outcome in
multiple myeloma (MM) patients treated with autologous stem cell transplant (ASCT). The depth of response is one
of the most relevant factors to predict patient’s outcome, however the definition of CR through standard criteria
has shown several limitations.
Methods: In this study we evaluated the minimal residual disease (MRD) in 50 consecutive MM patients who
underwent an up-front tandem ASCT in our center, using a single-tube six-colors flow cytometry assay (FC)
based on intra-cytoplasmic immunoglobulin (cy-Ig) light chains ratio evaluated on patient-specific plasma cells
(PC) immune profile, in a real-life setting.
Results: With a sensitivity up to 10−5, clonal-PC were documented by FC in 36.4 % (12/33) of patients in conventional
CR after second transplant. The number of flow MRD-negative patients significantly increased after induction
and first ASCT, but not between first and second transplant. The 5-years progression-free survival (5ys-PFS) of
flow MRD-negative patients after second transplant was significantly better than patients who remained MRD-positive
considering both all patients (5ys-PFS: 70 % vs 5 %) and patients in CR according to standard criteria (5ys-PFS:
67 % vs 0 %).
Conclusions: FC remission through cy-Ig light ratio on PC sub-populations is a sensitive, highly informative,
low-cost and routinely applicable MRD assay, a powerful tool in treatment response evaluation and a crucial
marker of outcome in MM.
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Background
Minimal residual disease (MRD) monitoring by multipa-
rameter flow cytometry (FC) is a powerful tool for treat-
ment efficacy and outcome prediction in hematological
malignancies and several reports are focusing on its
clinical relevance in multiple myeloma (MM) patients
[1–9], in order to better subcategorize the quality of
response compared to other approaches [10–13].
However, the identification and standardization of a
sensitive, reproducible and clinically relevant analyt-
ical approach is still under consideration for inter-
national consensus [14, 15] and therefore, FC is not
routinely performed in the current clinical practice,
being most of MM MRD assessment by FC reported
into controlled clinical trials [16–18].
In this study, we developed a 6-colors single-tube FC
assay for MRD monitoring, based on intra-cytoplasmic
immunoglobulin (cy-Ig) light chains ratio on patient-
specific plasma cell (PC) immune profile. This approach
was employed on 50 consecutive MM patients who
underwent an up-front tandem autologous stem cell
transplant (ASCT) and our 5 years follow-up analysis
showed that this inexpensive and sensitive test can effi-




From January 2006 to January 2012, 50 consecutive MM
patients, diagnosed according to International Myeloma
Working Group criteria [19] and treated in our Institu-
tion with an up-front tandem ASCT-based therapeutic
program entered the study. Baseline patient characteris-
tics are described in detail in Table 1. Two cases of IgD
myeloma have also been included, previous studies sug-
gesting that this myeloma subtype, treated with ASCT,
shows a similar prognosis as other myeloma patients
[20]. We have also included a plasma cell leukemia, con-
sidering that its clinical course was similar to other mye-
loma patients in which MRD negativity was never
achieved. All patients were stratified at diagnosis on the
basis of cytogenetic assessment [21]. Median follow-up
was 60 months (24–108). All patients provided written
informed consent for scientific purposes.
Flow cytometry
At diagnosis, FC analysis of the PC surface markers was
performed on erythrocytes-lysed EDTA-anti-coagulated
bone marrow (BM) samples using a 6-colors panel of
antibodies (Fitc/PE/PerCP/PE-Cy7/APC/APC-Cy7) and
the “Duo-lyse” program of the Becton Dickinson Bio-
science (BDB) Lyse-Wash-Assistant according to the 1)
CD28/CD138/CD45/CD38/CD33/CD20; 2) CD38/CD138/
CD45/CD56/CD117/CD19 antibodies combinations. The
PC Surface-Aberrant-Markers (SAM) were used as
patient-specific immune profile to document cy-Ig light
chains restriction utilizing a single-tube 6-color intra-
cytoplasmic staining: 3) cy-Ig lambda/cy-Ig kappa/CD19/
CD38/SAM+/CD45 at diagnosis and, for MRD monitor-
ing, after induction and at day +100 after both first and
second transplant. For cytoplasmic staining cells were
washed twice in PBS prior to staining, fixed and perme-
abilized using the Cytofix & Cytoperm kit (BDB) according
to manufacturer’s recommendations, incubated with the
monoclonal antibodies cocktail for 20 min at 4 °C, washed
in PBS and promptly acquired. All the antibodies were
from BDB but CD28, CD33 and CD138 from Beckman
Coulter. Light scatter and CD38 signal was used for PC
gating. A minimum of 2x103 PC were acquired. If not
Table 1 Baseline patient characteristics (n = 50)
Parameter N (%)
Sex, male 29 (58)
Median age at diagnosis, yrs. (range) 56 (41–68)
Diagnosis
IgG 20 (40 %)
IgA 11 (22 %)
IgD 2 (4 %)
Light chain 16 (32 %)
Plasma cell leukemia 1 (2 %)










Na (a) 1 (2)
Cytogenetic analysis [21]
High risk 6 (12 %)
Intermediate risk 8 (16 %)
Standard risk 35 (70 %)
Na (a) 1 (2 %)
Induction treatment
VAD (b) 23 (46)
Novel agents (c) 27 (54)
Up-front tandem ASCT (d) 50 (100)
(a) Na not available. (b) VAD Vincristine, Adryamicin, Dexamethasone (2
courses). (c) Novel agents: Bortezomib-based regimes (n = 21, 3 courses),
Immunomodulators only (n = 6, 3 courses). (d) ASCT autologous stem
cell transplant
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available, the whole stained sample was consumed. A
sample was considered suitable form MRD evaluation
when at least 150 PC were counted. Markers expression
was reported as percentage of positive cells within the
CD38-positive population. To differentiate between
normal and neoplastic PC, the kappa/lambda ratio was
evaluated on the whole CD38-positive PC population
and on any of the CD38 sub-populations. Patients were
considered FC positive for residual disease (flow MRD-
positive) when a PC kappa/lambda ratio either <0.5
or >4.0 was documented [22]. The CD19-positive BM
lymphocytes (identified as CD45-strong expression
and intermediate side-scatter signals), were utilized as
internal control for kappa/lambda ratio staining.
Overall, a total of 200 BM samples were processed
within 24 h from collection for MRD evaluation using
a BDB FACSCanto flow cytometer with FACSDiva
software.
Statistics
Data were analyzed using Statistical Package of Social
Sciences software (SPSS, version 17.0, Chicago, USA). The
correlation between treatment response by standard
criteria [23] and FC assessment according to check-point
of the therapeutic program was performed using the
Chi-square test (Fisher or Pearson) and Anova test for
categorical and quantitative variables, respectively.
Progression-free survival (PFS) curves were calculated by
the Kaplan-Meier method and compared using the two-
side log-rank (Mantel-Cox) test. Two-sided P values <0.05
were considered as statistically significant.
Results
The PC surface aberrant markers expression documented
at diagnosis is shown in Table 2. For MRD evaluation, gat-
ing on CD38-bright population in combination with the
side scatter, a median of 2317 (range 187–59609) PC was
acquired and analyzed on up to 3.0 x 106 total BM cells
(median total events acquired: 1.01 x 106, range 1.19 x
105–3.02 x 106), with a median of 0.2 % (range 0.03–53)
PC out of total BM leucocytes, at a sensitivity level
up to 10−5. Eleven samples (5.5 %) were inadequate
(hemodiluted) for MRD analysis and not considered
for further analysis.
On the whole CD38-bright PC population, cy-Ig light
chains restriction was documented in 35 % of samples
after treatment. However, gating on CD38/SAM sub-
populations (CD19neg, CD45weak/neg, CD56pos,
CD117pos, CD33pos) alone or in combination, clonal-
PC were overall identified in 62.5 % of samples after
treatment, being CD117 the most informative single
SAM for clonal-PC detection. Moreover, in a consider-
able proportion of samples with percentage of CD19neg
CD45weak/neg and CD56pos PC below the normal
threshold, clonal PC were easily identified by cy-Ig light
chains ratio after treatment (Table 2). Co-presence of
normal and neoplastic PC was observed in 100 % of
MRD-positive cases (Fig. 1). Focusing to patients in
conventional CR, cy-Ig light chains ratio on SAM sub-
populations documented clonal-PC in 36.4 % after sec-
ond transplant (12/33) and in 43.2 % of overall patients
irrespective to the check-point of the therapeutic pro-
gram (32/74), including BM samples with a SAM per-
centage below the normal threshold.
A significant decrease of clonal-PC was observed
between induction and first transplant (63 % vs 5 %;
P < 0.0001), but not between first and second ASCT
(5 % vs 1 %; P = 0.412). Treatment response by standard
and FC criteria, according to check point of the thera-
peutic program, is shown in Fig. 2. Compared to conven-
tional CR, a lower rate of immunophenotypic CR (flow
MRD-negative) was documented in all check-points of the
therapeutic program (28 % vs 16 % after induction, 54 %
vs 32 % after fist and 66 % vs 48 % after second ASCT).
The 5ys-PFS of flow MRD-negative patients after second
transplant was significantly better compared to MRD-
positive (5ys-PFS 70 % vs 5 %, respectively; P < 0.0001,
Fig. 3a). According to flow MRD assessment, patients
in conventional CR showed a significant difference in
5ys-PFS after second transplant (5ys-PFS 67 % vs 0 %






MRD-negative by cy-Ig light chains ratio on
SAM percentage above the normal threshold 6, 7
(Putative surface MRD-positive)
(% of samples)
MRD-positive by cy-Ig light chains ratio on
SAM percentage below the normal threshold 6, 7
(Putative surface MRD-negative)
(% of samples)
CD19neg 98 % CD19neg ≥30 % 2.5 % CD19neg <30 % 26 %
CD45weak/neg 63 % CD45weak/neg ≥6 % 38 % CD45weak/neg <6 % 39 %
CD56pos 74 % CD56pos ≥15 % 15 % CD56pos <15 % 27 %
CD117pos 41 % CD117pos ≥1 % 0 % CD117pos <1 % na
CD33pos 26 % CD33pos ≥6 % 60 % CD33pos <6 % 0 %
PC plasma cells, SAM surface aberrant marker, SAM% calculated within the CD38pos PC population, MRD minimal residual disease, cy-Ig cytoplasmic
immunoglobulin, na not applicable
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for MRD-positive and MRD-negative patients, respect-
ively; P < 0.0001, Fig. 3b). After induction, we found a
significant higher rate of conventional CR and flow
MRD-negative cases in patients who received a novel
agents-based treatment compared with those treated
with VAD regimen (10/27, 37 % vs 4/23, 17.4 %; P = 0.042
and 6/27, 22.2 % vs 2/23, 8.7 %; P = 0.039, respectively).
Interestingly, this difference was also evident, but not
statistically significant, after first and second transplant.
Moreover, 5-ys-PFS curves of MRD-negative patients
were absolutely similar among patients who received
novel agents vs VAD as induction treatment prior first
ASCT (data not shown).
Discussion
Some of the PC SAM can be detected at low levels in
healthy individuals and non-neoplastic PC can exhibit
immunophenotypic characteristics overlapping with
myeloma cells [6]. Loss of CD19 and CD56 expression
are, in fact, commonly observed in clonal-PC popula-
tion, however both features occur in subsets of poly-
clonal populations as well [7]. To overcome this
potential pitfall, we develop an original 6-colors single-
tube FC assay, based on cy-Ig light chains ratio on
patient-specific PC immune profile for MRD monitor-
ing in MM. The current manuscript describes a real-life
single center study that evaluates the clinical relevance
of this approach on 50 consecutive MM patients who
underwent an up-front tandem ASCT, on a 5 years
follow-up analysis. At the best of our knowledge, this is
the first report describing an extensively, single center,
flow-MRD monitoring based on cy-Ig light chains ratio
evaluated on PC sub-populations in myeloma patients
after transplant in a real-life setting.
Fig. 1 Flow cytometry gating strategy for MRD assessment: representative analysis of a bone marrow sample. a CD38bright PC population,
b CD45+ Lymphocytes (Ly), c surface membrane expression of CD19 and CD56 assessed on CD38bright PC, d cy-Ig Kappa/Lambda
ratio on CD19+ PC (normal; ratio 1.9); e cy-Ig Kappa/Lambda ratio on CD56+ PC (clonal; ratio 0.01); f cy-Ig Kappa/Lambda ratio on CD19+ Ly
utilized as internal control (normal; ratio 1.8); g cy-Ig Kappa/Lambda ratio on the PC and Ly populations; h populations hierarchy
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Sensitivity is one of the most important factors in
MRD identification and this assay has shown to dis-
criminate between reactive and neoplastic PC in sam-
ples with very low cell count as pleural effusion and
cerebrospinal MM infiltration [24]. Our selected anti-
body panel included all the antigens more recently rec-
ommended by The European Myeloma Network and
International Clinical Cytometry Societies for PC
characterization [25]. However, to discriminate between
normal and malignant PC, our strategy focused on the
intra-cytoplasmic light chains expression evaluated on
PC sub-populations identified by the expression of
normal and SAM. We found the use of light chains re-
striction as an important adjunct to the use of surface
markers, with the capability to identify clonal-PC
hidden in the context of a normal PC population in
43.2 % of patients in conventional CR, at a sensitivity
up to 10−5. The baseline flow testing allowed to utilize
a 6-color single-tube assay for MRD detection, however
it is not an absolute requirement. If not performed at
diagnosis, a baseline characterization can be performed
after treatment to identify patient’s SAM to utilize for
disease monitoring if the aberrant PC population ex-
ceeds the 10−5 threshold.
The sensitivity of FC for MRD detection is dependent
on the number of cell analyzed and several studies
pointed on the total number of cells acquired [26].
Using the light scatter and CD38 signal for PC gating,
2317 PC on a median of 1.01 x 106 total events were re-
corded and analyzed, being 94.5 % the percentage of
specimens evaluable for analysis. Acquisition of an
higher number of events, up to 3–5 x 106, is currently
considered the best practice for MRD monitoring [26].
In MRD-negative cases, we are now increasing the
number of total processed events, staining the whole
BM sample and recording the whole PC population of
the sample, to reach the 10−5 limit of detection in all
samples. Check the quality of the specimen is also of
primary relevance in these samples.
PC clonality was documented on a minority (35 %) of
samples when the cy-Ig light chains ratio was evaluate on
the whole CD38 positive population. By contrast, gaiting on
minor PC subsets expressing one or more SAM, neoplastic
PC were documented in the majority of sample after treat-
ment, including BM samples with a SAM percentage below
the normal threshold. Thereafter, this approach allowed de-
termining, in a more reliable way, whether a small PC frac-
tion with a putative aberrant phenotype (e.g., CD19neg or
CD56pos) was representative of an abnormal clone or of a
non-clonal PC sub-population despite the putative SAM ex-
pression, documenting that the light chains restriction is an
important adjunct to the use of surface markers.
Co-presence of normal (polyclonal) and neoplastic
(clonal) PC was documented in all MRD positive samples
showing that, despite the tumor persistence, a fraction of
normal PC emerge from the BM environment. For this
reason, cy-Ig light ratio evaluated in the whole CD38 posi-
tive PC population identified clonal PC in a minority of
cases after treatment, by contrast it was very informative if
evaluated on the SAM sub-populations, even in samples
with SAM percentage below the normal threshold. More-
over, BM clearance, evaluated through the normal vs.
neoplastic PC ratio monitoring, could represent an early
surrogate marker of treatment efficacy.
Fig. 2 Patients in CR according to standard criteria and MRD negative from FC assessment in all check-points of the therapeutic program
Cordone et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:49 Page 5 of 8
FC confirmed to be more sensitive than standard
criteria. In fact, among patients in conventional CR, flow-
MRD positivity was documented in 36.4 % of patients
after second transplant and in 43.2 % of overall patients
irrespective to the check-point of the therapeutic program,
strongly supporting the relevance of cy-Ig light ratio
Fig. 3 5-years PFS curves according to MRD assessment by FC after second transplant: all patients (a); patients in CR according to
standard criteria (b)
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assessment by flow MRD monitoring in this era of “next-
generation-flow” [1, 7]. A strong correlation between the
depth of response evaluated by FC and patient’s clinical
outcome emerged from our study and, despite the rela-
tively low number of patients included into the study, the
significant difference in terms of PFS between MRD-
positive and MRD-negative patients validates our ap-
proach of flow-MRD monitoring in MM.
The second ASCT has not added statistically signifi-
cant advantages in term of depth of response when
assessed by FC, confirming the less widely use of tan-
dem ASCT in MM [27]. However, in clinical practice,
the opportunity to perform a second ASCT is a major
point of concern in MRD-positive patients after the
first transplant. Further studies are warranties to ad-
dress this relevant issue.
Flow MRD-negative patients after the second transplant
showed a significantly better clinical outcome in terms of
PFS when compared with flow MRD-positive, confirming
the relevance of MRD assessment by marrow examination
in all patients, irrespective to conventional CR and in
agreement with previously published studies [16–18].
More relevant, the depth of response evaluated by FC was
able to stratify patients in conventional CR into two
groups (flow MRD-pos vs. neg) with a significantly differ-
ent clinical outcome. Finally, as recently reported [28],
also in our study the impact of post-transplant flow MRD
assessment was independent of induction regimen prior
transplant (i.e., novel agents vs VAD).
Conclusion
MRD testing needs to be accurately defined for uniform
response criteria to be utilized as an endpoint for drug
approval in MM. We found the use of light chains evalu-
ation on PC sub-populations as an important adjunct to
the use of surface markers for distinguish abnormal from
normal PC and a significant predictor of clinical out-
come in MM patients treated with and up-front tandem
ASCT. Our experience supports the role of the light
chains as key markers in multicolor flow-MRD monitor-
ing for treatment response evaluation, to maximize the
therapy benefit and improve clinical management in
MM in the next future.
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